ScreenerHero

CAI Caris Life Sciences, Inc.

NYSE · US · Healthcare · Biotechnology · carislifesciences.com
26.66USD-5.81%Mkt Cap: 8.66B $P/E: 3.20

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare usin…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap8.66B USD
Enterprise Value7.42B USD
Revenue (TTM)989.60M USD
Gross Profit539.17M USD
Net Income (TTM)-68.09M USD
Revenue/Share3.49 USD
Last Price26.66 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.8K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)3.20
P/E (Forward)75.47
PEG—
EV/EBITDA42.63
EV/Revenue7.50
P/S7.84
P/B13.11
EPS (TTM)1.69
EPS (Forward)0.36
52W Range
14.1963% of range34.12
52W High34.12 USD
52W Low14.19 USD
Profitability
Gross Margin66.40%
Oper. Margin10.21%
EBITDA Margin17.58%
Profit Margin-8.38%
ROE-11.79%
ROA-6.05%
Growth
Revenue Growth45.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF83.16M USD
CapEx (TTM)16.26M USD
FCF Margin6.39%
FCF Yield0.73%
Net Debt-340.71M USD
Net Debt/EBITDA-1.96
Balance Sheet
Debt/Equity0.74
Current Ratio5.53
Quick Ratio4.75
Book Value/Sh2.09 USD
Cash/Share2.81 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)29.08 USD
Upside (mean)+9.1%
Target Range22.00 USD – 38.00 USD
22.00+9.1% to mean38.00
# Analysts13
Ownership
Shares Out.282.60M
Float134.87M
Insiders48.79%
Institutions56.54%
Short Interest
Short Ratio2.6d
Short % Float11.58%
Short % Out.4.72%
Shares Short13.33M
Short (prev mo.)14.95M
Technical
SMA 5024.75 (+7.7%)
SMA 20021.23 (+25.6%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)5.40M
Avg Vol (10d)4.24M
Technical Indicators
RSI (14)51.5
MACD1.6256
MACD Signal2.0416
MACD Hist.-0.4160
BB Upper34.71 USD
BB Middle28.73 USD
BB Lower22.75 USD
BB Width41.62%
ATR (14)1.493 USD
Vol Ratio (20d)0.63x